The relative brain signal variability increases in the behavioral variant of frontotemporal dementia and Alzheimer's disease but not in schizophrenia
Timo Tuovinen,Jani Häkli,Riikka Rytty,Johanna Krüger,Vesa Korhonen,Matti Järvelä,Heta Helakari,Janne Kananen,Juha Nikkinen,Juha Veijola,Anne M Remes,Vesa Kiviniemi,Howard Rosen,Bradford C Dickerson,Kimoko Domoto-Reilly,David Knopman,Bradley F Boeve,Adam L Boxer,John Kornak,Bruce L Miller,William W Seeley,Maria Luisa Gorno Tempini,Scott McGinnis,Maria Luisa Mandelli,on behalf of the Frontotemporal Lobar Degeneration Neuroimaging Initiative
DOI: https://doi.org/10.1177/0271678x241262583
2024-06-21
Journal of Cerebral Blood Flow & Metabolism
Abstract:Journal of Cerebral Blood Flow &Metabolism, Ahead of Print. Overlapping symptoms between Alzheimer's disease (AD), behavioral variant of frontotemporal dementia (bvFTD), and schizophrenia (SZ) can lead to misdiagnosis and delays in appropriate treatment, especially in cases of early-onset dementia. To determine the potential of brain signal variability as a diagnostic tool, we assessed the coefficient of variation of the BOLD signal (CVBOLD) in 234 participants spanning bvFTD (n = 53), AD (n = 17), SZ (n = 23), and controls (n = 141). All underwent functional and structural MRI scans. Data unveiled a notable increase in CVBOLD in bvFTD patients across both datasets (local and international, p < 0.05), revealing an association with clinical scores (CDR and MMSE, r = 0.46 and r = −0.48, p < 0.0001). While SZ and control group demonstrated no significant differences, a comparative analysis between AD and bvFTD patients spotlighted elevated CVBOLD in the frontopolar cortices for the latter (p < 0.05). Furthermore, CVBOLD not only presented excellent diagnostic accuracy for bvFTD (AUC 0.78–0.95) but also showcased longitudinal repeatability. During a one-year follow-up, the CVBOLD levels increased by an average of 35% in the bvFTD group, compared to a 2% increase in the control group (p < 0.05). Our findings suggest that CVBOLD holds promise as a biomarker for bvFTD, offering potential for monitoring disease progression and differentiating bvFTD from AD and SZ.
neurosciences,endocrinology & metabolism,hematology